TrialNCT04856930Phase 2Completed
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa
Study sponsor: Vanda Pharmaceuticals
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2022-07-15Actual
Enrollment · participants149Actual
Source updated2025-09-22Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.